Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 5, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions

Cancer of the Head and Neck

Interventions

DRUG

INCAGN01876

agonistic antihuman GITR mAb

DRUG

INCMGA00012

humanized, hinge-stabilized, IgG4κ mAb that recognized human PD-1

BIOLOGICAL

DPV-001

autophagosome cancer vaccine

Trial Locations (1)

RECRUITING

Portland Providence Medical Center, Portland

All Listed Sponsors

lead

Providence Health & Services

OTHER